[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joel  Lewis", "age": 53, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 870664, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jack W. Callicutt CPA", "age": 56, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 492624, "exercisedValue": 0, "unexercisedValue": 4125}, {"maxAge": 1, "name": "Dr. Pol F. Boudes M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": 720637, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Robert  Tritt", "title": "General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Katstra", "title": "Head of CMC & Pharmaceutical Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.8, "open": 1.79, "dayLow": 1.72, "dayHigh": 1.79, "regularMarketPreviousClose": 1.8, "regularMarketOpen": 1.79, "regularMarketDayLow": 1.72, "regularMarketDayHigh": 1.79, "beta": 0.939, "forwardPE": -2.6363635, "volume": 32881, "regularMarketVolume": 32881, "averageVolume": 62739, "averageVolume10days": 56800, "averageDailyVolume10Day": 56800, "bidSize": 1000, "askSize": 900, "marketCap": 107616736, "fiftyTwoWeekLow": 1.08, "fiftyTwoWeekHigh": 2.47, "fiftyDayAverage": 1.844, "twoHundredDayAverage": 1.7616, "currency": "USD", "enterpriseValue": 152046656, "floatShares": 42520952, "sharesOutstanding": 61848700, "sharesShort": 2113605, "sharesShortPriorMonth": 2107436, "sharesShortPreviousMonthDate": 1701302400, "dateShortInterest": 1703808000, "sharesPercentSharesOut": 0.0342, "heldPercentInsiders": 0.31279, "heldPercentInstitutions": 0.1469, "shortRatio": 25.7, "shortPercentOfFloat": 0.055, "impliedSharesOutstanding": 61848700, "bookValue": -0.859, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -45444000, "trailingEps": -0.76, "forwardEps": -0.66, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": 0.53982306, "SandP52WeekChange": 0.20347583, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GALT", "underlyingSymbol": "GALT", "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "firstTradeDateEpochUtc": 1031146200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7b109f3e-2059-3335-8b86-82e0d6c5f2dc", "messageBoardId": "finmb_1065415", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.74, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 20362000, "totalCashPerShare": 0.329, "totalDebt": 62559000, "quickRatio": 1.935, "currentRatio": 2.054, "returnOnAssets": -1.2208999, "freeCashflow": -22427124, "operatingCashflow": -35502000, "financialCurrency": "USD", "trailingPegRatio": null}]